Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials

  title={Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials},
  author={Andrew D. Siderowf and Dag Aarsland and Brit Mollenhauer and Jennifer G. Goldman and Bernard M. Ravina},
  journal={Movement Disorders},
Biomarkers have the potential to improve diagnosis and prognosis, and guide clinical treatment decisions. In research, biomarkers can be used for patient selection and as outcome measures in clinical trials. A range of biochemical and imaging biomarkers are relevant to patients with Lewy body disorders, including PD, PD dementia, and dementia with Lewy bodies. Dopaminergic imaging is used for differential diagnosis of parkinsonian disorders versus tremor disorders without dopamingeric deficits… 

Lewy Body Dementias: A Coin with Two Sides?

An overview of the neuropathological and clinical features, current diagnostic criteria, biomarkers, and management of LBD is provided, with a special focus on α-synuclein markers.

Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials

There are opportunities to improve the landscape of LBD clinical trials by harmonizing clinical assessments and biomarkers across cohorts and research studies, developing and validating outcome measures in LBD, engaging the patient community to assess research needs and priorities, and incorporating biomarker and genotype profiling in study design.

Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors

This review covers molecules that might act as the biomarkers of Parkinson's disease and suggests that microRNA-based analysis may bring considerable progress, especially if it is combined with α-syn data.

Early stages of Parkinson’s disease: aspects of the diagnosis and therapy

Symptomatic pharmacotherapy, which compensates for dopaminergic deficiency and is able to alleviate motor and some nonmotor symptoms of parkinsonism, as well as some neuroprotective treatment options, have been analysed and the role of amantidines is described in detail.

Cognitive Impairment and Dementia in Parkinson Disease.

Living with Lewy body dementia. Treatment, survival & quality of life.

The importance of pharmacological and non-pharmacological management in LBD, particularly in view of the poor prognosis compared to the general population, is emphasised, addressing physical, social and psychological needs.

Diagnostic Value of the CSF α-Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies

CSF α-syn RT-QuIC is a robust biomarker for prodromal DLB and indicates that MCI-LB patients against cognitively unimpaired controls with mild cognitive impairment due to probable Lewy body disease are identified.

DAT imaging and myocardial MIBG scintigraphy for Lewy body diseases: A clinical‐neuroimaging study

Clinical‐neuroimaging data of 450 LBD patients was analyzed to answer the question which marker is more useful for identifying the three major LBD subtypes: Parkinson's disease, dementia with Lewy bodies, and the autonomic‐sleep variant.

HFBD: a biomarker knowledge database for heart failure heterogeneity and personalized applications

The HF biomarker knowledge database (HFBD), established by manually collecting the data and knowledge from literature in PubMed, provides a unique resource for the systematic understanding of HF heterogeneity and personalized diagnosis and treatment of HF in the era of precision medicine.



Biomarkers for cognitive dysfunction in Parkinson's disease.

  • L. Kalia
  • Psychology, Biology
    Parkinsonism & related disorders
  • 2018

Biomarkers for dementia and mild cognitive impairment in Parkinson's disease

This review summarizes studies from the past 25 years that have assessed the potential biomarkers of dementia and mild cognitive impairment in Parkinson's disease patients and concludes that no biomarker has as yet been validated.

Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.

In PD, high neurofilament light chain protein, low Aβ1-42, and high heart fatty acid-binding protein at baseline were related to future PDD as analyzed by Cox proportional hazards regression models, providing new insights into the etiology of PDD.

Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies

Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis

Imaging amyloid deposition in Lewy body diseases

Global cortical amyloid burden is high in dementia with Lewy bodies (DLB) but low in Parkinson disease dementia, and data suggest that β-amyloid may contribute selectively to the cognitive impairment of DLB and may contribute to the timing of dementia relative to the motor signs of parkinsonism.

Cognitive decline in Parkinson disease

New genetic evidence indicates that in addition to the APOE*ε4 allele (an established risk factor for AD), GBA mutations and SCNA mutations and triplications are associated with cognitive decline in PD, whereas the findings are mixed for MAPT polymorphisms.

Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.

A role for tau copathology in the Lewy body diseases is supported, particularly in patients with DLB and in PD-impaired patients, even in those without elevated amyloid levels.

Amyloid PET Imaging in Lewy body disorders.

  • P. DonaghyA. ThomasJ. O'Brien
  • Psychology, Biology
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2015